The FDA-Food and Drug Administration after detailed analysis, concluded that the first vaccine against Covid-19 to be considered for distribution in the US.
According to them, the Pfizer vaccine "meets the predicted success criteria" adding that the agency will soon give the green light for mass use of the vaccine.
Today (Tuesday, December 8) the agency published 2 separate analyzes; one of its staff scientists and one of the manufacturers of the Pfizer vaccine itself in collaboration with German partners, BioNTech.
After detailed analysis, the FDA outlined the "known benefits" of the vaccine, the main one being reducing the risk with Covid-19 for at least 7 days after the second dose. So far, the Pfizer vaccine is said to require two doses for complete protection.
The other advantage of this FDA approved vaccine is the reduction of the confirmed risk of Covid-19 after the first dose and before the second dose as well as the "reduction of the confirmed severe risk of Covid-19 at any time after taking the first dose .
Other findings of the agency analysis show that "no threatening concerns or side effects were identified that would prevent the issuance of an emergency authorization". Serious side effects are rare, while the most common ones included headaches or nausea.
Such conclusions are considered a success and a historic moment, as critics feared that the vaccine could only prevent the mild and moderate form of the disease.
Meanwhile, a 90-year-old woman has become the first patient in the world to get the Pfizer vaccine for Covid-19 after its approval in the UK. The National Health Service (NHS) launched its largest vaccination campaign this Tuesday (December 8th).
Burimi: The Wall Street Journal & NPR
